insulin lispro

(redirected from Lispro)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

insulin lispro

(lĭs′prō′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by a reversal in the order of lysine and proline in the B chain, used in the treatment of type 1 and type 2 diabetes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

insulin lispro

A synthetic insulin with a very rapid onset and short duration of action. Diabetic patients typically use it immediately before meals to prevent postprandial hyperglycemia. Its absorption is more rapid than regular insulin. It is made by reversing the amino acids lysine and proline in the beta chain of the insulin polypeptide (hence its name lispro).
See also: insulin
Medical Dictionary, © 2009 Farlex and Partners

insulin lispro

Very rapidly-acting INSULIN. A brand name is Humalog.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Doses administered were 12, 24 and 48 U for both Dance 501 (assuming 13% delivery efficiency) and lispro.
"The availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin," said Mike Mason, senior vice president, Connected Care and Insulins.
In the present study, CGMS data showed that lispro had a similar effect as aspart on blood glucose fluctuation and hypoglycemia.
###and on average daily###2 weeks of Ramadan and then Insulin###Pre-evening meal: lower with###insulin lispro Mix25###patient
In-Process Revision: <121> Insulin Assays: "In Vitro Cell-Based Bioidentity Test for Insulin Glargine and Insulin Lispro" as additional method in the USP chapter <121> Insulin Assays.
CSII therapy via insulin pump was started with lispro (basal infusion rate of 0.
In this double-blind, randomized, crossover study, 36 patients with type 1 diabetes used individualized doses of either BioChaperone Lispro or Humalog as the short acting insulin in their multiple daily injection regimen, over two periods of 14 days.
Currently available data are limited to preliminary reports of results from phase 3 studies, which show pegylated insulin lispro has superior glucose-lowering efficacy compared with Gla-100 in patients with T2DM.
"The benefit is reflected in the [higher, faster] peak insulin values seen with both lispro and aspart compared with human insulin" said Dr.
The study population consisted of a total of 122 type 2 diabetic patients who were commenced on insulin treatment for the first time either with insulin lispro premix 50/50 three times daily (n=60) or insulin aspart premix 70/30 two times daily (n=62) at the outpatient clinic of endocrinology of Yeditepe University Hospital.
Humalog Mix[R] 25 (75 percent insulin lispro protamine suspension and 25 percent insulin lispro injection) is a mixture of insulin lispro solution (Humalog[R]), that acts rapidly with insulin lispro protamine suspension, an intermediate acting, blood glucose towering agent.